Crowdonomics
All companies
JelikaLite logo

JelikaLite

Operating

JelikaLite Corp.

Healthcare · Technology · New York, DE · Founded 2021

Precision autism through light

Post-money valuation ⓘ
$11.8M
As of Jan 2022 · from Reg CF Offering (2021) · pre-money + amount raised, not a traded price
Total raised
$616,996
Across 1 round since 2021
Latest share price
$0.65
Reg CF · Common Stock · Dec 2021 offering price

Financials

FY2019–FY2021 · from SEC filings · hover any figure for its source
$0
−$58K
2019
$0
−$166K
2020
$0
−$54K
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019 reviewed*
FY2020 reviewed*
FY2021
Income statement
Revenue
$0
$0
$0
Cost of goods sold
$0
$0
$0
Net income
-$58,032
-$166,212
-$53,894
Taxes paid
$0
$0
$0
Balance sheet
Cash
$73,516
$104,845
$81,163
Accounts receivable
$0
$0
$0
Total assets
$73,516
$104,845
$91,163
Short-term debt
$2,848
$388
$388
Long-term debt
$100,000
$300,000
$470,000
Total liabilities
$102,848
$300,388
$470,388
Other
Headcount
—
4
4

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$11.1M
pre-money
Reg CF · Common · Dec 2021

Blue bars are the pre-money valuation the company stated for a priced round.

Fundraising history

Raised $617K / $1.1MInvestors 125Post-money $11.8M

Team

10 people
Eugenia SteingoldFounder
Co-Founder & Chief Science Officer

Dr. Eugenia Steingold is a NYS licensed psychologist with extensive experience in experimental research. Dr. Steingold received her PhD from Princeton University, specializing in psycholinguistics and cognitive psychology and she was a PostDoc in Harvard University, specializing in cognitive and linguistic development.

Katya SverdlovFounder
Co-Founder & CEO

Katya Sverdlov, CFA, Esq., received her BA in Economics from Cornell University and her JD degree from Brooklyn Law School. Ms. Sverdlov has over a decade of experience working in progressively senior positions in investment banking and portfolio risk management. Most recently, she was the founding attorney of a fast paced, boutique Trusts and Estates and Special Needs Law Firm in New York.

Liza Logounova
Chief Operating Officer & Secretary

Liza Logounova has over a decade experience as a product manager in the environmental markets space, most recently holding a role of a Senior Technology Manager in Global Forest Watch department of the World Resources Institute (WRI). Liza helped build and bring to market various products within WRI, such as TerraMatch and Global Forest Watch Professional (GFW Pro). Prior to that Liza has been a director in the IHS Markit, where she played a lead role in Markit Environmental team’s full software product lifecycle for supporting international and national government and private initiatives to reduce water pollution, deforestation and carbon emissions. First half of her professional career she worked as a Vice President in the technology division of a major Investment Bank (Goldman Sachs).

Luis DeTaboada
Chief Technology Officer

Luis DeTaboada has several decades of experience bringing photobiomodulation medical devices to market. Most recently, he was a CTO of LiteCure, a company which, in late 2020, was successfully sold to DJO Global. Mr. De Taboada holds over one hundred patents, patent applications, and peer-reviewed publications in the field of tPBM therapy. He conducted preclinical and clinical studies. He designed and developed devices, developed protocols, and obtained regulatory approvals. He launched domestic and international sites and managed all technical aspects of multicenter, multinational clinical studies—including the first-in-man clinical studies of tPBM Therapy for neurological applications.

Ali Mostashari, PhD
Advisor

Member of World Economic Forum, is co-founder of LifeNome (https://www.lifenome.com), a precision health AI company. He is assisting JelikaLite in the development of the AI platform infrastructure.

Anne-Marie Maman
Advisor

Executive Director, Princeton Entrepreneurship Council at Princeton University. Founded 3 startup companies, each with innovative, leading-edge technology; licensed IP, led all aspects of the businesses, and negotiated acquisition of 1 company for nearly $10 million within 3 years of formation. She is advising JelikaLite in matters of fund-raising and corporate governance.

Dr. Michael Hamblin, PhD
Advisor

Dr. Michael Hamblin PhD is an associate professor at Harvard Medical School and an Associate Chemist in Massachusetts General Hospital. He is a world leading specialist on photobiomodulation, with over 280 peer-reviewed publications, mostly on phototherapy. He is advising JelikaLite on existing studies on photobiomodulation and he is introducing JelikaLite to clinicians in the area.

Dr. Robert K. Naviaux, MD
Advisor

Dr. Naviaux is a Professor of Genetics, in the Departments of Medicine, Pediatrics, and Pathology. He directs a core laboratory for metabolomics at UCSD. He is the co-founder and a former president of the Mitochondrial Medicine Society (MMS), and a founding associate editor of the journal Mitochondrion. He is an internationally known expert in human genetics, inborn errors of metabolism, metabolomics, and mitochondrial medicine. He is the discoverer of the cause of Alpers syndrome---the oldest Mendelian form of mitochondrial disease---and the developer of the first DNA test to diagnose it. Dr. Naviaux's lab has developed a number of advanced technologies like biocavity laser spectroscopy and mtDNA mutation detection by mass spectrometry.

Maxim Kalachenkov
Director

Maxim is a lawyer with decades of experience in multiple areas of law. He studied at The Institute of State and Law (ISL) of the Russian Academy of Sciences (RAS), the largest scientific legal center in the Russian Federation. Since 2000, Maxim has worked as the Head of the Legal Department at Mitro International Limited.

Show 1 more person
Yuli Fradkin MD
Advisor

Principal Investigator on the Phase I clinical trial. Associate Professor at Rutgers University, specialist in autism therapy and research.

Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFewer than 300 holders of record

Filed 1 of 5 annual reports (FY2021–FY2025)

125 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-USep 30, 20220001665160-22-002552
    EDGAR
  • Form C-ARMay 2, 20220001665160-22-001396
    EDGAR
  • Form C-UJan 20, 20220001665160-22-000117
    EDGAR
  • Form C/AJan 10, 20220001665160-22-000069
    EDGAR
  • Form C/AJan 6, 20220001665160-22-000035
    EDGAR
  • Form C/ADec 22, 20210001665160-21-002294
    EDGAR
  • Form CDec 15, 20210001665160-21-002202
    EDGAR
Source: ManualCIK 0001894308DEShare price $0.65

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.